This year progress has been made in understanding the mechanisms as well as the treatments for both pancreatic neoplasia and inflammatory pancreatic diseases. Advances in genetic sequencing, bioinformatics, and tissue procurement have resulted in more detailed descriptions of the molecular and functional changes that underlie pancreatic adenocarcinoma (PDA). As described in the review by Smrita and Leach [1] , molecular analysis of this cancer in several studies has shown distinct patterns that were translated into meaningful categories. Thus, PDA can now be classified as featuring networks characteristic of squamous neoplasms, early development, and endocrine and exocrine differentiation enriched. Molecular signatures of immune cells, most prominently B and T cells, resulted in another category, the immunogenic pancreatic cancer phenotype. Distinct patterns of stromal cell activation were also observed. An exciting feature of these classifications is that they appear to correspond to patient survival. With these data in hand, it will be significant to see whether these different tumor subtypes will exhibit distinct therapeutic responses.
In the review by Saluja et al. [2] , advances in therapeutic nonsurgical approaches that show promise for PDA are reviewed and include a history of the development of current therapies. Based on the molecular pancreatic cancer phenotypes discussed above and by Smrita and Leach, there are reasons to be hopeful that some of the newer approaches to therapy, such as enhancing drug access by reducing the barrier presented by the extracellular matrix, may be useful in selecting patient subgroups. The dramatic responses observed in melanoma with check-point inhibitors suggest that detailed knowledge of tumor antigens as well as local immunosuppressive mechanisms could greatly enhance future pancreatic cancer immune therapies. This contribution also summarizes preliminary studies on a drug known as Minnelide, a promising new compound that may have activity against a range of neoplasms, including PDA. Though the precise mechanism of action for this drug remains unclear as discussed by the authors, its effects on the stroma and deposition of extracellular matrix and cancer stem cells have been described in PDA animal models. A phase I study is being performed by the developers of Minnelide, and data from this trial should be available in the near future.
In Hartmann and Friess's [3] overview of pancreatic surgery, issues related to inflammatory and neoplastic diseases are reviewed. As found with other illnesses, management of acute pancreatitis by a multidisciplinary team at high-volume centers is associated with a lower risk of death from acute pancreatitis. Delaying surgical intervention by first using supportive therapy and then using invasive procedures in a step-wise manner with increasing levels of invasiveness has become central to the management of patients with suspected or documented infected pancreatic necrosis. Several shortterm and long-term follow-up studies of different surgical approaches for the treatment of chronic pancreatitis pain have been completed and are reviewed. First, though there appears to be advantages of organ-sparing procedures (such as the Beger and Frey procedures which themselves seem to have similar outcomes) over the short term with respect to pain relief and other parameters, in the long term advantages of organ preservation approaches may be lost. Second, compared with pancreatoduodenectomy, duodenum-preserving pancreatic head resections may result in a better quality of life. Third, the authors favor recent studies advocating for surgical intervention early in the course of chronic pancreatitis for those with pain and dilated pancreatic ducts. This review also commented on the challenges of managing pancreatic cystic neoplasms and underscored the importance of considering comorbidities using the Charlson Comorbidity Index or other such scales in selecting patients for surgery. Though the surgical approaches to pancreatic cancer remained similar over this review period, active discussion on the use of neoadjuvant (chemo or chemo-radiation therapy prior to surgery) remains an important topic of active but challenging investigation that has been expertly reviewed [4] .
In Park's [5] review of clinical chronic pancreatitis, genetic and other mechanistic advances are discussed, along with approaches to diagnosing and treating this disease. Though minor mutations in the cystic fibrosis transmembrane conductance regulator have been linked to pancreatitis, an important study he cites by Maleth et al. demonstrated that alcohol can selectively suppress the function and levels of this key transporter in pancreatic epithelial cells. Diagnosis of chronic pancreatitis, particularly in those with early disease, continues to be a challenge. Trikudanathan et al.
(cited by Park) showed a poor correlation between endoscopic ultrasonography (EUS) features and pancreatic histology, raising questions about our current diagnostic criteria. Whether EUS elastography will lead to diagnose and detect chronic pancreatitis is still under study.
A role for long-term antioxidants in chronic pancreatitis treatment has been the subject of a number of studies, but a consensus is lacking for benefit in part due to heterogeneity in both therapies and patient characteristics. High rates of osteoporosis in chronic pancreatitis were again reported, but the cause of this important disease complication remains unclear, and correlation with serum vitamin D levels has been weak. Trials need to determine whether chronic pancreatitis patients with osteoporosis are also cigarette smokers because of the known effect of smoke toxins on bone mineralization and fracture risk. Finally, a multicenter consortium assembled and funded by the United States National Institutes of Health will examine relationships between chronic pancreatitis, pancreatic cancer, and diabetes. In that context, Mohapatra et al. [6] provided an excellent summary relating diabetes to a recently described pancreatic exocrinopathy that is characterized by prominent pancreatic fibrosis but lacks other features of chronic pancreatitis. As fibrosis is known to underpin the development of other gastrointestinal neoplasms, such as liver cancer, it is significant to speculate response that this might contribute to the increased risk of pancreatic cancer in people with diabetes.
Elmunzer's [7] review on endoscopic approaches to pancreatic disease reviews issues related to diagnosing and treating pancreatic disease. He provides a practical and detailed discussion of the use of selfexpanding metallic stents for the treatment of biliary obstruction caused by chronic pancreatitis. Development of other specialized technologies is also reviewed. Though surgical vs endoscopic drainage for chronic pancreatitis is discussed in a manner similar to that in Friess's review on pancreatic surgery, the two authors provide contrasting views that may reflect their expertise and experience.
In the final contribution, Gukovskaya et al. [8] update our knowledge of the cellular and molecular mechanisms of pancreatitis. Known for its central role in degrading intracellular organelles, proteins, and lipids, autophagy is required for normal cell function. A series of studies has documented autophagic-lysosome dysfunction in experimental and human pancreatitis; the mechanism of the dysfunction remains under study. Changes in pancreatic acinar cell calcium signaling have long been linked to the initiation of acute pancreatitis. Newly described inhibitors of calcium-entry can correct the disease-related calcium signals in model systems.
They have now been found to reduce pancreatitis responses in experimental models and could be clinically useful. Finally, a large epidemiologic study showed a convincing decrease in pancreatitis risk for patients receiving simvastatin. These findings are reminiscent of the growing body of data suggesting that statins substantially reduce the progression of chronic liver disease and raise the possibility that this class of drugs might have values in reducing disease severity or progression in recurrent acute or chronic pancreatitis.
